682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility

BACKGROUND: Fidaxomicin use is increasing to treat Clostridioides difficile infection (CDI) following clinical treatment guideline updates placing it as first-line therapy. This puts a selection pressure on the development of fidaxomicin resistance, which has been associated with in vitro fitness co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzales-Luna, Anne J, Le, Thanh, Eubank, Taryn A, Karim, Md Ekramul, Jahangir Alam, M, Begum, Khurshida, Garey, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677244/
http://dx.doi.org/10.1093/ofid/ofad500.744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677244/
http://dx.doi.org/10.1093/ofid/ofad500.744

Ejemplares similares